Genzyme Institutes Further Rationing Of Cerezyme, Fabrazyme To Build Inventory
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite last year's manufacturing problems and the resulting shortages, biotech says 85 percent of U.S. Cerezyme patients have returned.